

# Supplementary Information

**Table S1.** Demographic variables of individuals recruited for this study.

	Healthy controls (n = 24)	Cohort 1 Stroke Patients (n = 68)	Cohort 2 Stroke Patients (n = 101)	Cohort 3 Metabolic Syndrome Patients (n = 94)
<b>Age (Years ± SEM)</b>	39.0 ± 8.10	45.5 ± 2.07	59.7 ± 1.39	39.4 ± 9.15
<b>Gender</b>				
<b>Female, n (%)</b>	6 (25.0)	28 (41.14)	39 (38.61)	27 (28.72)
<b>Male, n (%)</b>	18 (75.0)	40 (58.82)	62 (61.39)	67 (71.28)
<b>Ethnicity</b>	Asian	Asian	Asian	Asian
<b>Risk Factors, n (%)</b>				
<b>Hypertension</b>	NA	41(63.08)	78 (77.59)	28 (29.78)
<b>Diabetes</b>	NA	27(41.54)	45 (44.55)	31 (33.00)
<b>Hyperlipidaemia</b>	NA	31(47.69)	76 (75.24)	74 (78.72)

**Table S2.** Validation of miRNA expression in all stroke samples. Expression of 10 highly significant miRNAs ( $p < 0.0001$ ) were validated using qPCR. Expression of the miRNAs was determined in all stroke samples (regardless of timepoints) as well as samples clustered according to their timepoints. Data is represented as a relative expression with respect to healthy controls ± SEM.

miRNAs	All Stroke	Acute Stroke			Recovery	
		Day 1	Day 2	Day 7	<6 months	<2 years
<b>miR-135b</b>	3.62 ± 1.86	4.19 ± 1.50	3.59 ± 2.49	2.69 ± 1.72	2.86 ± 2.68	2.79 ± 1.89
<b>miR-145</b>	1.65 ± 0.70	1.25 ± 0.80	1.30 ± 0.93	1.49 ± 0.93	1.89 ± 0.57	1.13 ± 0.15
<b>miR-210</b>	2.07 ± 1.36	2.29 ± 1.54	2.55 ± 2.01	1.44 ± 0.79	1.08 ± 0.79	1.66 ± 1.31
<b>miR-494</b>	1.74 ± 0.76	1.39 ± 0.42	2.35 ± 3.12	0.99 ± 0.60	1.25 ± 0.99	2.14 ± 2.40
<b>miR-498</b>	4.19 ± 2.51	4.44 ± 3.57	4.11 ± 2.79	1.38 ± 1.19	2.18 ± 2.87	5.85 ± 6.59
<b>miR-126</b>	0.81 ± 0.52	0.95 ± 0.90	0.80 ± 0.25	0.67 ± 0.54	0.61 ± 0.53	0.57 ± 0.49
<b>miR-182</b>	0.87 ± 0.57	0.61 ± 0.13	0.68 ± 0.44	0.73 ± 0.52	0.62 ± 0.57	0.55 ± 0.47
<b>miR-183</b>	0.56 ± 0.36	0.62 ± 0.48	0.46 ± 0.43	0.38 ± 0.25	0.30 ± 0.20	0.41 ± 0.36
<b>miR-342-3p</b>	0.63 ± 0.35	0.64 ± 0.20	0.58 ± 0.40	0.36 ± 0.21	0.63 ± 0.55	0.74 ± 0.62
<b>miR-361-5p</b>	0.68 ± 0.28	0.73 ± 0.22	0.60 ± 0.31	0.53 ± 0.26	0.56 ± 0.48	0.67 ± 0.56

**Table S3.** Circulating miRNAs identified in stroke and stroke-related co-morbidities. With respect to our 105 miRNAs cluster, several studies reporting on miRNAs implicated in the pathology of stroke and its risk factors are compiled in this table. Among the 105 miRNAs, those highlighted in bold exhibit similar expression profiles when compared to reports involving rat stroke models.

**Table S3.** *Cont.*

**Table S3.** *Cont.*

**Table S3.** *Cont.*

**Table S3.** *Cont.*

miRNAs	Fold change	Tan <i>et al.</i> (2009)	Jeyaseelan <i>et al.</i> (2008)		Liu <i>et al.</i> (2010)		Dharap <i>et al.</i> (2009)	Lim <i>et al.</i> (2010)	Origin	Circulating miRNA (serum/plasma) expression in stroke co-morbidity
		Human	Rat		Rat		Rat	Rat		
		Blood	Blood	Brain	Blood	Brain	Brain	Brain		
		(2 years)	(24 h)	(24 h)	(24 h)	(24 h)	(24 h)	(24 h)		
miR-668	2.54	↑							Heart	
<b>miR-671-5p</b>	2.91						↑			
miR-675	4.52									
<b>miR-7</b>	-2.23	↓	ND	↓	↑	ND	↓	↓	Brain	
miR-886-5p	-2.43									
miR-920	3.48									
<b>miR-92a</b>	-1.42			↓	ND		↓	Endothelial cell		↓ Atherosclerosis
miR-93*	-1.63									
miR-933	1.44									
miR-943	2.98									
miR-96	-2.10							Platelet		↓ Coagulation
<b>miR-99a</b>	6.40						↑			

**Table S4.** Expression of human specific miR-920. Expression of miR-920 was determined in all stroke samples across various time points. Data is represented as a relative expression with respect to healthy controls  $\pm$  SEM.

miRNA	Acute Stroke			Recovery	
	Day 1	Day 2	Day 7	<6 months	<2 years
miR-920	2.20 $\pm$ 0.640	1.82 $\pm$ 1.196	0.26 $\pm$ 0.752	2.70 $\pm$ 0.551	1.50 $\pm$ 0.205

© 2014 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (<http://creativecommons.org/licenses/by/3.0/>).